Subsequently, the silencing of RGS5 also suppressed the functions of resmetirom in the activation of STAT3 and NF-κB signaling pathways in the NAFLD/NASH cell model (Figure 3G). Here, RGS5 is linked to metabolic dysfunction-associated steatotic liver disease.